DOD Biotech Shares Owned By Institutions vs. EBITDA
| DOD Stock | 1.95 0.01 0.51% |
For DOD Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of DOD Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well DOD Biotech Public utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between DOD Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of DOD Biotech Public over time as well as its relative position and ranking within its peers.
DOD |
DOD Biotech Public EBITDA vs. Shares Owned By Institutions Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining DOD Biotech's current stock value. Our valuation model uses many indicators to compare DOD Biotech value to that of its competitors to determine the firm's financial worth. DOD Biotech Public is one of the top stocks in shares owned by institutions category among its peers. It also is one of the top stocks in ebitda category among its peers totaling about 142,360,971 of EBITDA per Shares Owned By Institutions. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the DOD Biotech's earnings, one of the primary drivers of an investment's value.DOD EBITDA vs. Shares Owned By Institutions
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
DOD Biotech |
| = | 2.38 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
DOD Biotech |
| = | 338.82 M |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
DOD EBITDA Comparison
DOD Biotech is currently under evaluation in ebitda category among its peers.
DOD Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on DOD Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of DOD Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the DOD Biotech's important profitability drivers and their relationship over time.
Use DOD Biotech in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DOD Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DOD Biotech will appreciate offsetting losses from the drop in the long position's value.DOD Biotech Pair Trading
DOD Biotech Public Pair Trading Analysis
The ability to find closely correlated positions to DOD Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DOD Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DOD Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DOD Biotech Public to buy it.
The correlation of DOD Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DOD Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DOD Biotech Public moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DOD Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your DOD Biotech position
In addition to having DOD Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Size And Style ETFs Thematic Idea Now
Size And Style ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Size And Style ETFs theme has 1105 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Size And Style ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in DOD Stock
To fully project DOD Biotech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of DOD Biotech Public at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include DOD Biotech's income statement, its balance sheet, and the statement of cash flows.